CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Kaedi Bio
Company Type: Therapeutic development
Main focus: Developing cell therapies to treat solid malignancies
Company stage: Clinical
Diseases: Solid malignancies
Genome-editing tool: CRISPR-Cas9
Funding stage:
Location: Nanjing, Jiangsu, China
Website: www.kaedibio.com
Pipeline: www.kaedibio.com/index.php
Partners:
Kaedi Bio is a clinical-stage biotechnology company focused on expanding cell therapies that are currently approved for various haematological malignancies to treat solid cancers. The company’s focus surrounds advancing CAR-T cell therapy by using their proprietary KD-SmCAR platform, a synthetic biology discovery platform to develop novel CAR’s. Kaedi Bio is investigating the use of CRISPR-Cas9 to engineer the surface of T cells in CAR-T development and improve cell therapy efficacy in solid cancers.
